|
Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2 Study
|
Amicus |
|
Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease
|
Valerion |
|
Program Update for Phase 1/2 Pompe Study by Amicus Therapeutics
|
Amicus |
|
Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data
|
Amicus |
|
Amicus Therapeutics Presents Scientific Findings and Preclinical Data for Pompe Program
|
Amicus |
|
Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Novel Treatment Paradigm for Pompe Disease
|
Amicus |
|
10 Years of Enzyme Replacement Therapy
|
IPA |
|
NeoGAA Phase 3 Trial Begins
|
Genzyme |
|
BioMarin Update for the Pompe Community
|
Biomarin |
|
IPA Statement on Biomarin's June 9th announcement it will seek to out-license BMN-701
|
Tiffany |
